Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Editorial

Page Path

HOME
ARTICLE CATEGORY
Editorial

Editorial

Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?

Nae-Yun Heo

Clin Mol Hepatol. 2017;23(2):125-127. Published online June 23, 2017

DOI: https://doi.org/10.3350/cmh.2017.0106

View: 7822 Download: 145 Web of Science: 3 Crossref: 3

Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?

Do Young Kim

Clin Mol Hepatol. 2017;23(2):123-124. Published online June 23, 2017

DOI: https://doi.org/10.3350/cmh.2017.0107

View: 7616 Download: 120

Is scheduled second chemoembolization necessary for early stage hepatocellular carcinoma showing complete response after first chemoembolization?

Jin Wook Chung

Clin Mol Hepatol. 2017;23(1):31-33. Published online March 16, 2017

DOI: https://doi.org/10.3350/cmh.2017.0102

View: 6783 Download: 105 Web of Science: 1 Crossref: 1

Transient elastography can be integrated into routine clinical practice for the evaluation of portal hypertension?

Beom Kyung Kim

Clin Mol Hepatol. 2017;23(1):27-30. Published online March 24, 2017

DOI: https://doi.org/10.3350/cmh.2017.0101

View: 7835 Download: 116 Web of Science: 3 Crossref: 3

Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?

Byung-Cheol Song

Clin Mol Hepatol. 2016;22(4):439-442. Published online December 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0108

View: 8356 Download: 113 Web of Science: 1 Crossref: 1

Does obesity increase the risk of hepatocellular carcinoma in chronic hepatitis B patients?

Byoung Kuk Jang

Clin Mol Hepatol. 2016;22(3):336-338. Published online September 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0104

View: 8865 Download: 123 Web of Science: 2 Crossref: 1

Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?

Hyung Joon Yim

Clin Mol Hepatol. 2016;22(2):238-240. Published online June 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0103

View: 9008 Download: 97 Web of Science: 1 Crossref: 1

What we know about paracentesis induced circulatory dysfunction?

Jeong Han Kim

Clin Mol Hepatol. 2015;21(4):349-351. Published online December 24, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.4.349

View: 10688 Download: 170 Web of Science: 4 Crossref: 5

P53 expression in hepatocellular carcinoma: influence on the radiotherapeutic response of the hepatocellular carcinoma

Yu Rim Lee, Soo Young Park

Clin Mol Hepatol. 2015;21(3):230-231. Published online September 30, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.3.230

View: 7316 Download: 75 Web of Science: 12 Crossref: 10

Hepatitis C virus infection in patients with hemophilia in Korea: Is antiviral therapy effective and safe?

Woo Sun Rou, Byung Seok Lee

Clin Mol Hepatol. 2015;21(2):122-124. Published online June 26, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.2.122

View: 8740 Download: 107 Web of Science: 2

Regression of liver cirrhosis: Orthodoxy or paradigm shift?

Su Jong Yu

Clin Mol Hepatol. 2015;21(1):22-23. Published online March 25, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.1.22

View: 7008 Download: 91 Web of Science: 2 Crossref: 1

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question

Hyun Woong Lee

Clin Mol Hepatol. 2014;20(4):345-346. Published online December 24, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.4.345

View: 5817 Download: 71 Web of Science: 1 Crossref: 1

Occult hepatitis B virus infection: clearance or disguise?

Jin-Wook Kim

Clin Mol Hepatol. 2014;20(3):249-250. Published online September 25, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.3.249

View: 7941 Download: 57

Are patients with alcohol-related fatty liver at increased risk of coronary heart disease?

Dong Hyun Sinn, Yong-Han Paik

Clin Mol Hepatol. 2014;20(2):151-153. Published online June 30, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.2.151

View: 6076 Download: 80

Do cirrhotic patients with a high MELD score benefit from TIPS?

Won Hyeok Choe

Clin Mol Hepatol. 2014;20(1):15-17. Published online March 26, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.1.15

View: 6834 Download: 47 Web of Science: 4 Crossref: 3

Liver stiffness measurement: Is it a non-invasive substitution for HVPG?

Soung Won Jeong

Clin Mol Hepatol. 2013;19(4):367-369. Published online December 28, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.4.367

View: 6918 Download: 52 Crossref: 4

Chasing after novel non-invasive markers to identify advanced fibrosis in NAFLD

Wonseok Kang, Seung Up Kim

Clin Mol Hepatol. 2013;19(3):255-257. Published online September 30, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.3.255

View: 6469 Download: 54 Crossref: 2

Noninvasive markers: a double-edged sword that stratifies nonalcoholic steatohepatitis

Goh Eun Chung, Donghee Kim

Clin Mol Hepatol. 2013;19(2):116-119. Published online June 27, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.2.116

View: 7646 Download: 95

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?

Young Kul Jung, Ju Hyun Kim

Clin Mol Hepatol. 2013;19(1):26-28. Published online March 25, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.1.26

View: 7090 Download: 51 Crossref: 4

Elevated serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease

Byoung Kuk Jang

Clin Mol Hepatol. 2012;18(4):357-359. Published online December 21, 2012

DOI: https://doi.org/10.3350/cmh.2012.18.4.357

View: 7958 Download: 97 Crossref: 27

Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients

Woo Jin Chung

Clin Mol Hepatol. 2012;18(3):268-271. Published online September 25, 2012

DOI: https://doi.org/10.3350/cmh.2012.18.3.268

View: 6381 Download: 49 Crossref: 1

Noninvasive diagnostic criteria for hepatocellular carcinoma

Han Chu Lee

Clin Mol Hepatol. 2012;18(2):174-177. Published online June 26, 2012

DOI: https://doi.org/10.3350/cmh.2012.18.2.174

View: 7201 Download: 56 Crossref: 3

The effect of alanine aminotransferase dynamics on predicting sustained virological response in chronic hepatitis C virus infection

Tae Yeob Kim

Clin Mol Hepatol. 2012;18(1):29-31. Published online March 22, 2012

DOI: https://doi.org/10.3350/kjhep.2012.18.1.29

View: 7865 Download: 37 Crossref: 4

A tool for communication with decision-makers: limitations and utilization of studies on cost of illness

Kun-Sei Lee

Clin Mol Hepatol. 2011;17(4):258-260. Published online December 26, 2011

DOI: https://doi.org/10.3350/kjhep.2011.17.4.258

View: 5727 Download: 35 Crossref: 1

Durability of antiviral therapy for chronic hepatitis C after achieving sustained virological response

Jeong Heo

Clin Mol Hepatol. 2011;17(3):180-182. Published online September 30, 2011

DOI: https://doi.org/10.3350/kjhep.2011.17.3.180

View: 6868 Download: 34

Percutaneous interventional procedures in an era of liver transplantation

Young Seok Kim

Clin Mol Hepatol. 2011;17(2):96-98. Published online June 23, 2011

DOI: https://doi.org/10.3350/kjhep.2011.17.2.96

View: 6433 Download: 37

Liver function tests as indicators of metabolic syndrome

Han Chu Lee

Clin Mol Hepatol. 2011;17(1):9-11. Published online March 21, 2011

DOI: https://doi.org/10.3350/kjhep.2011.17.1.9

View: 6213 Download: 50 Crossref: 4

Which treatment modality should we choose for advanced hepatocellular carcinoma?

Do Young Kim

Clin Mol Hepatol. 2010;16(4):353-354. Published online December 31, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.4.353

View: 6530 Download: 65

Hypoxia-inducible factor 1, hepatocellular carcinoma and angiogenesis

Jin-Wook Kim

Clin Mol Hepatol. 2010;16(3):278-279. Published online September 30, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.3.278

View: 6468 Download: 34 Crossref: 3

From Invasive to Intuitive: The Emerging Role of Non-Invasive Models in Hepatic Decompensation

Akhil Deshmukh, Rakhi Maiwall

Received August 13, 2024 Accepted August 13, 2024

DOI: https://doi.org/10.3350/cmh.2024.0661 [Accepted]

PDF

View: 1023 Download: 18

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Video abstract

Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation
Impact Factor

14.0
First decision

07 Days

Publication after acceptance

04 Days

*Last 12 months

MOST VIEWED MOST CITED

MOST VIEWED (Last 6 months)

Viewed By 6976	MAFLD: How is it different from NAFLD?
Viewed By 6227	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 5317	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5152	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4665	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

MOST CITED (2023-2025)

Cited By 298	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 266	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 170	MAFLD: How is it different from NAFLD?
Cited By 92	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 88	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051 FAX: +82-2-703-0071 E-mail: cmh_journal@ijpnc.com

Copyright © The Korean Association for the Study of the Liver.

COUNTER

TODAY : 1665

TOTAL : 2551385